What Icosagen Group does

Icosagen Group is an Estonian-based Contract Research, Development, and Manufacturing Organization (CRDMO) founded in 1999 as a spin-off from the University of Tartu, headquartered in Tartu, Estonia with a North American business development office in San Francisco. The company provides integrated antibody and protein services spanning the full biologics lifecycle — antibody discovery (phage display, B-cell panning via its HybriFree platform, hybridoma sequencing, immunization), antibody development and engineering (bispecifics, affinity maturation, humanization), antibody-drug conjugate conjugation, recombinant protein production, cell line development, developability assessment, protein purification and analytics, cell-based assays, and GMP manufacturing at 50 L, 200 L, and 1000 L single-use bioreactor scales. Its competitive position rests on three proprietary technology platforms — QMCF Technology (CHO-based episomal mammalian expression with yields up to 1 g/L), IcoCell (GMP-compliant stable cell line development), and HybriFree (B-cell antibody discovery) — supplemented by HEK293-based VLP technology for membrane protein presentation, Reagent 007 (a proprietary transfection reagent), and a partnership with ProBioGen for GlymaxX-based ADCC-enhanced antibody production. A 2023 acquisition of Carterra's LSA platform added high-throughput label-free antibody screening.

Name

Icosagen Group

Legal name

Icosagen AS

Website

https://icosagen.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

1–10 employees

Short description

Icosagen Group is an Estonian CRDMO providing integrated antibody discovery, protein production, cell line development, and GMP manufacturing services to global biotech, pharma, IVD, and academic clients using proprietary QMCF, IcoCell, and HybriFree platforms.

Ownership category

akta.pro rank

Product category

Biologics Contract Development and Manufacturing

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835), Pharmaceutical Preparations (2834)

akta.pro primary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

akta.pro secondary industries

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Contract research services
• Antibody development services
• GMP biomanufacturing
• Protein production services
• Cell line development

Headquarters

HQ city

Tartu

HQ country

Estonia

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. CRDMO Contract Research and Manufacturing Services: Icosagen provides integrated CRO and CDMO services spanning the full antibody and protein development lifecycle from discovery to GMP manufacturing. Revenue is generated through project-based contracts for antibody discovery, antibody development and engineering, protein production, cell line development, process development, and GMP manufacturing services. The company operates co-located teams to minimize technology transfer risks and accelerate molecule development through CMC.
2. Catalogue Products (Antibodies, Proteins, Transfection Reagent): Sale of catalog research reagents including antibodies across categories (infectious diseases, cardiovascular markers, inflammation, neurobiology, metabolic diseases, renal, latex allergens, isotype controls) and recombinant proteins. Also includes Reagent 007 transfection reagent. Products sold directly via e-commerce shop and through regional distributors.
3. Diagnostic Products and Food Microbiology Testing: Icosagen provides food microbiology testing services and sells diagnostic-grade antibody and protein products for in vitro diagnostics use.

Pricing tiers

Go-to-market motion3 records

Distribution channels8 records

Marketing channels6 records

Core offering

Icosagen Group operates as a CRDMO (Contract Research, Development, and Manufacturing Organization) providing integrated CRO and CDMO services spanning the full antibody and protein development lifecycle, from discovery through GMP manufacturing. The company also sells catalog products including research and diagnostic antibodies, recombinant proteins, and a proprietary transfection reagent (Reagent 007), and offers QMCF Technology for licensing. Services cover antibody discovery, antibody development and engineering, antibody-drug conjugates, recombinant protein production, cell line development, protein purification and analytics, GMP manufacturing, cell-based assays, and early antibody developability assessment.

Product overview

Icosagen Group operates as a CRDMO (Contract Research, Development, and Manufacturing Organization) providing integrated biologics services from discovery to GMP manufacturing. The company's portfolio includes proprietary technology platforms (QMCF Technology for transient mammalian expression, IcoCell Technology for stable cell line development, and HybriFree Technology for B-cell screening), service modules covering the full antibody and protein development lifecycle (Antibody Discovery, Antibody Development & Engineering, Antibody-Drug Conjugates, Protein Production, Cell Line Development, Protein Purification & Analytics, GMP Manufacturing, Cell-Based Assays, Early Antibody Developability Assessment, and Food Microbiology Testing), and catalog products (Diagnostic Antibodies and Proteins). The company also offers Reagent 007 as a transfection reagent and BioBlock® as a nasal spray product. Services leverage CHO and HEK293 cell-based expression systems with proprietary technologies and third-party GlymaxX® technology for ADCC enhancement.

Differentiator

Problem solved

Functional benefit

Brands

• QMCF Technology: Proprietary CHO-based mammalian expression technology for recombinant protein production with high yields up to 1g/L
• IcoCell
• HybriFree Technology
• BioBlock

Products and services

• CRDMO Services Integrated Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) services supporting the full lifecycle of antibody and protein programs from discovery through GMP manufacturing, for pharmaceutical and biotechnology companies worldwide.
• Antibody Discovery Antibody discovery services including phage display, B-cell panning (HybriFree), hybridoma sequencing, and immunization for identifying high-affinity binders, for pharmaceutical and biotechnology clients.
• Antibody Development & Engineering Antibody engineering services including bispecific antibody engineering, affinity maturation, and humanization for lead optimization of therapeutic antibody candidates.
• Antibody-Drug Conjugates (ADCs) Conjugation of proteins, primarily antibodies, with drugs, peptides, dyes, or oligonucleotides to create antibody-drug conjugates for targeted therapeutic delivery.
• Protein Production Recombinant protein production services using proprietary QMCF Technology including transient expression, bispecific antibodies, membrane protein expression via VLP technology, and ADCC enhancement via afucosylation (GlymaxX).
• Cell Line Development Generation of GMP-compliant CHO-based stable cell lines using the IcoCell platform for production of recombinant proteins and monoclonal antibodies.
• Protein Purification & Analytics Advanced protein analytics services for purity, functionality, and stability assessment including a wide array of modern analytical methods.
• GMP Manufacturing Good Manufacturing Practice manufacturing with 50L, 200L, and 1000L single-use bioreactors, including upstream and downstream process development for recombinant proteins and antibodies.
• Early Antibody Developability Assessment Early developability screening combining in silico prediction with experimental validation including biochemical, biophysical, and functional characterization to identify promising antibody candidates.
• Cell-Based Assays Cell-based assay services for antibody characterization and functional testing.
• Food Microbiology Testing Microbiological testing services for food quality control and food safety compliance.
• Reagent 007 A next-generation peptide-based chemical transfection reagent optimized for efficient delivery of DNA into mammalian (CHO, HEK293) and insect (Sf9) cell lines for recombinant protein and antibody production, VLP generation, and CRISPR applications.
• BioBlock® Nasal Spray A nasal spray containing neutralizing antibodies derived from bovine colostrum, developed for blocking viral transmission (originally tested against SARS-CoV-2).
• Diagnostic Antibodies (Catalog) Research and in vitro diagnostic antibodies covering cardiovascular markers, infectious diseases, inflammation markers, neurobiology, metabolic diseases, renal markers, and latex allergens, sold through the Icosagen e-commerce shop and regional distributors.
• Proteins (Catalog) Recombinant proteins for research and diagnostic use including cytokines, growth factors, and antigens, sold through the Icosagen e-commerce shop and regional distributors.
• QMCF Technology (Licensing) Patented CHO-based mammalian expression technology available for licensing, for rapid recombinant protein production with high yields (up to 1g/L) using episomal vectors that ensure stable expression levels.

Named customers16 records

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Ten partnerships are on record, tiered strategic, core and minor.

• Tartu University Hospital (Tartu Ülikooli Kliinikum)strategicStrategic or Co-development Partner · 27 May 2024Tartu University Hospital, North Estonia Medical Centre, and Icosagen have joined forces to develop and bring personalized CAR-T cell therapy to Estonian patients. Icosagen develops manufacturing processes, conducts preclinical tests, and produces GMP-compliant therapeutic cells. The hospital prepares clinical protocols, selects patients, and administers the therapy. This collaboration aims to make CAR-T therapy accessible to Estonian blood cancer patients within a few years.
• North Estonia Medical Centre (Põhja-Eesti Regionaalhaigla)strategicStrategic or Co-development Partner · 27 May 2024North Estonia Medical Centre (Estonia's largest cancer treatment center serving over half of Estonia's cancer patients), Tartu University Hospital, and Icosagen collaborate on personalized CAR-T cell therapy development. The hospital contributes clinical expertise, patient selection, cell collection, and therapy administration, while Icosagen handles manufacturing process development and GMP cell production.
• CarterracoreTechnology or Integration · 21 March 2023Icosagen acquired Carterra's LSA (Ligand Presentation System / Label-Free Screening) platform, a high-throughput antibody screening technology. The integration enhances Icosagen's antibody discovery capabilities, improving the speed, flexibility, and throughput of antibody screening and characterization services for global biotech and pharmaceutical clients.
• ProBioGencoreTechnology or IntegrationIcosagen has a long-standing partnership with ProBioGen to use its GlymaxX technology for generating fully afucosylated ADCC-enhanced antibodies. GlymaxX guarantees over 95% afucosylation and is universally applicable to new and existing antibody clones. Production timelines and final yields remain identical for both regular and afucosylated antibodies. The partnership enables rapid, multi-parallel ADCC potency enhancement studies for therapeutic antibody development.
• 2BScientificminorChannel Partner/ Reseller/ Distributor2BScientific (headquartered in Oxfordshire, UK) distributes Icosagen's immunological reagents and kits to the UK and Irish research market.
• Tokyo Future StyleminorChannel Partner/ Reseller/ DistributorTokyo Future Style distributes Icosagen's catalogue products (antigens and antibodies) and CRDMO services to Japanese and Taiwanese researchers and companies.
• Amyjet ScientificminorChannel Partner/ Reseller/ DistributorAmyjet Scientific distributes all Icosagen catalogue products for the Chinese market.
• Sapphire North AmericaminorChannel Partner/ Reseller/ DistributorSapphire North America sells Icosagen catalogue products for research and diagnostic use in the USA, Canada, and Mexico.
• AFSBiominorChannel Partner/ Reseller/ DistributorAFSBio distributes Icosagen proteins, antibodies, and ELISA kits in the USA and Canada.
• CedarlaneminorChannel Partner/ Reseller/ DistributorCedarlane sells Icosagen catalogue products in the USA and Canada.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Bio-Techne: Large publicly traded life sciences tools and reagents company offering catalog antibodies, proteins, and contract services. Overlaps with Icosagen's catalog product line (antibodies, recombinant proteins) and offers similar GMP-grade reagents, though at much larger scale with broader product breadth.
• Eurofins CDMO: Global CRO/CDMO division of Eurofins Scientific offering biologics manufacturing, cell line development, and analytical services. Broader portfolio with more standardized offerings and global footprint; competes for similar biotech outsourcing clients at scale Icosagen cannot match.
• Lonza Group: Swiss global leader in biologics CDMO offering mammalian cell line development, process development, and large-scale GMP manufacturing for mammalian and microbial biologics. Operates at vastly larger scale than Icosagen but competes for the same biotech outsourcing wallet share across discovery-to-GMP services.
• Samsung Biologics: South Korea-headquartered global CDMO with very large-scale mammalian GMP manufacturing capacity. Competes for late-stage and commercial biologics manufacturing contracts, particularly attractive to biotech clients seeking Asian manufacturing redundancy.
• WuXi Biologics: China-headquartered global biologics CDMO with end-to-end discovery, development, and manufacturing services. Largest Asian CDMO and a frequent competitor for biotech outsourcing, though geopolitical headwinds and Western onshoring trends create opportunity for European-based Icosagen.
• Cobra Biologics (Charles River Laboratories): Specialist CDMO within Charles River offering viral vector, plasmid DNA, and biologics manufacturing. Mid-sized comparable to Icosagen but with broader parent company infrastructure; competes for similar gene therapy and biologics development projects.

Direct peers

• AbCellera Biologics: Vancouver-based antibody discovery and development company with proprietary single-cell screening platform. Directly competes in antibody discovery services for biotech/pharma clients, with similar technology-forward positioning and focus on difficult-target antibody programs.
• Aldevron: US-based CDMO specializing in plasmid DNA, mRNA, recombinant proteins, and antibodies for biotech and gene therapy clients. Comparable mid-sized specialist CDMO with similar biologics manufacturing capabilities and customer profile of biotech startups and mid-pharma.
• GenScript ProBio: Singapore-headquartered CDMO subsidiary of GenScript offering antibody discovery, cell line development, and GMP manufacturing for biologics. Directly comparable end-to-end CRDMO model with mammalian expression focus, though at substantially larger scale with Asian manufacturing footprint.
• ProBioGen: Berlin-based specialist biologics CDMO offering cell line development (CHO), GMP manufacturing, and proprietary technologies (GlymaxX, AGE1). Direct competitor with similar scope; notably already a technology partner to Icosagen, making the comparison especially relevant for technology and market positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/icosagen-cell-factory

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries1 record

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Icosagen Group